Nektar Therapeutics (NKTR) has partnered with Merck KGaA and Pfizer Inc. to evaluate the combination of NKTR-255 with avelumab in urothelial carcinoma. Under the collaboration, Merck and Pfizer will include the combination of NKTR-255 plus avelumab in the new JAVELIN Bladder Medley study. Nektar will supply NKTR-255 for the trial.
NKTR-255 is wholly owned by Nektar. It is currently being evaluated in two separate clinical studies in both liquid and solid tumors.
Avelumab, which is marketed in the U.S. as BAVENCIO, is co-developed and co-commercialized by Merck KGaA and Pfizer Inc.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.